EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Phase II study of cladribine, idarubicin, and ara‐C ( CLIA ) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

Tapan M Kadia iD, Farhad Ravandi iD, Matteo Molica, Alex Bataller iD, Gautam Borthakur iD, Naval Daver iD, Elias Jabbour iD, Courtney D DiNardo iD, Naveen Pemmaraju iD, Nitin Jain iD, Alessandra Ferrajoli, Musa Ylimaz iD und 12 weitere

American Journal of Hematology · 2023-11 · 98 (11) · 1711-1720

DOI: 10.1002/ajh.27054 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 27.08.2023. Verfasst von Tapan M Kadia und 23 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Idarubicin, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The addition of cladribine, or sorafenib to standard chemotherapy have each demonstrated improved survival in patients with newly‐diagnosed acute myeloid leukemia (AML). We studied the combination of cladribine, idarubicin, and intermediate‐dose cytarabine (CLIA) in patients ≤65 years of age with newly diagnosed AML, fit to receive intensive therapy. Cladribine (5 mg/m2) IV was administered on days (D)1–5, cytarabine (1 g/m2) on D1‐5, and idarubicin (10 mg/m2) on D1‐3. Sorafenib was added to the CLIA backbone for patients with FLT3 ‐ITD mutated AML. 80 patients were enrolled: 65 with newly diagnosed AML and 15 with AML arising from previously treated MDS (ts‐AML). The median age was 55 years (range, 21–65). CR + CRi was 83% (54/65) and 27% in the untreated and ts‐AML cohorts, respectively; 74% and 75% of responding patients, respectively, had undetectable measurable residual disease (MRD). Among patients with FLT3 ‐ITD mutated AML receiving CLIA+sorafenib, the CR + CRi rate was 95%, with 81% negative for MRD. With a median follow‐up of 76 months, the 2‐ and 4‐year OS of 57% and 50% compared to 20%, and 13% for ts‐AML, respectively. Patients treated with CLIA+sorafenib had 2‐ and 5‐year OS rates of 63% and 59%, respectively. The most common Grade ≥3 adverse events were infection/fever, elevated bilirubin, rash, and nausea. CLIA was safe and effective in young, fit patients with newly diagnosed AML with inferior outcomes among patients with ts‐AML. The addition of sorafenib to CLIA in FLT3 ‐ITD mutated AML resulted in high rates of durable remission and excellent long‐term survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IdarubicinLeukemia, Myeloid, AcuteHumansMiddle AgedSorafenibCladribineCytarabineRemission InductionAntineoplastic Combined Chemotherapy Protocols

Substanzen

IdarubicinSorafenibCladribineCytarabine

Autor:innen und Institutionen

  • Departments of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Departments of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Division of Pharmacy, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Departments of Hematopathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Departments of Stem Cell Transplant, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Tapan M Kadia, Farhad Ravandi, Alex Bataller, Gautam Borthakur, Naval Daver, Elias Jabbour, Courtney D DiNardo, Naveen Pemmaraju, Nitin Jain, Musa Ylimaz, Prithviraj Bose, Rebecca Slack Tidwell, Kayleigh R Marx, Caitlin R Rausch, Rashmi Kanagal-Shamanna, Sa Wang, Marina Konopleva, Guillermo Garcia-Manero, Hagop Kantarjian

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Kadia, T. M., Ravandi, F., Molica, M., Bataller, A., Borthakur, G., Daver, N., Jabbour, E., DiNardo, C. D., Pemmaraju, N., Jain, N., Ferrajoli, A., Ylimaz, M., Bose, P., Tidwell, R. S., Marx, K. R., Rausch, C. R., Kanagal-Shamanna, R., Wang, S., Islam, R., …, & Kantarjian, H. (2023). Phase II study of cladribine, idarubicin, and ara‐C ( CLIA ) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. American Journal of Hematology, 98(11), 1711-1720. https://doi.org/10.1002/ajh.27054

Vancouver

Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, et al. Phase II study of cladribine, idarubicin, and ara‐C ( CLIA ) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. American Journal of Hematology. 2023;98(11):1711-1720. doi:10.1002/ajh.27054

BibTeX
@article{Kadia2023,
  author = {Kadia, Tapan M and Ravandi, Farhad and Molica, Matteo and Bataller, Alex and Borthakur, Gautam and Daver, Naval and Jabbour, Elias and DiNardo, Courtney D and Pemmaraju, Naveen and Jain, Nitin and Ferrajoli, Alessandra and Ylimaz, Musa and Bose, Prithviraj and Tidwell, Rebecca Slack and Marx, Kayleigh R and Rausch, Caitlin R and Kanagal-Shamanna, Rashmi and Wang, Sa and Islam, Rabiul and Champlin, Richard and Shpall, Elizabeth and Konopleva, Marina and Garcia-Manero, Guillermo and Kantarjian, Hagop},
  title = {Phase II study of cladribine, idarubicin, and ara‐C ( CLIA ) with or without sorafenib as initial therapy for patients with acute myeloid leukemia},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {11},
  pages = {1711--1720},
  doi = {10.1002/ajh.27054}
}
Kostenlos starten →